Accueil > Départements scientifiques > Département TERI > Immunosurveillance du cancer et ciblage thérapeutique
Immunosurveillance du cancer et ciblage thérapeutique
Objectifs
Le système immunitaire est l’une des principales barrières protégeant notre organisme du développent tumoral. Cependant, le système immunitaire peut aussi dans certaines circonstances faciliter le développement tumoral par des mécanismes encore peu connus. Notre objectif est donc d’identifier ces mécanismes impliquées dans la subversion du système immunitaire par les cellules cancéreuses et de développer des stratégies basées sur l’identification de l’immunogénicité des différentes formes de mort cellulaire et par la réactivation des mécanismes d’immuno-surveillance. Les modèles tumoraux sur lesquels nous travaillons sont le cancer du sein et de l’ovaire et le mélanome.
-
Christophe CAUX
Chef d’équipe
christophe.caux@lyon.unicancer.frCheney D – 3ème étage
Centre Léon Bérard
Membres de l'équipe
Principaux financements
INSERM
CNRS
Université Claude Bernard Lyon I
Institut National du Cancer (INCa)
Association pour la Recherche sur le Cancer (ARC)
Ligue Nationale contre le Cancer (Comités de l’Ain, de l’Ardèche, de la Drôme, du Puy de Dôme, du Rhône, de Savoie et de Saône et Loire)
Agence Nationale pour la Recherche (ANR)
Région Auvergne Rhône-Alpes
Lyon Biopole
Laboratoire d’Excellence (LabEx) DevWeCan (Grand Emprunt)
Fondation pour la Recherche Médicale (FRM)
Principales collaborations nationales
Institut Gustave Roussy (Villejuif) / Laurence ZITVOGEL
INSERM U851 (Lyon) / Jacqueline MARVEL et Thierry WALZER
Institut de Recherche Thérapeutique IRT UN Unité INSERM 892, Centre de Recherche en Cancérologie Nantes-Angers (Nantes) / Henri VIE
Institut Curie (Paris) / Sebastian AMIGORENA, Vassili SOUMELIS, …
Université Pierre et Marie Curie (Paris) / Benoit SALOMON et Gilles MARODON
INSERM U631 (CIML, Marseille) / Marc DALOD et Bernard MALISSEN
Laboratoire d’Immunologie des Tumeurs, Centre de Recherche en Cancérologie de Marseille (Marseille) / Daniel OLIVE
INRA (Jouy en Josas) / Nicolas BERTHO et Isabelle SWARTZ-CORNIL
Institut de Biologie Structurale (Grenoble) / Franck FIESCHI
Institut de Génétique Moléculaire de Montpellier (Montpellier) / Marc PIECHAZYCK
Société BASF (Lyon) / Valérie ANDRE et Nicolas BECHETOILLE
Groupe Hospitalier Pitié Salpêtrière (Paris) / Dr Jean-Baptiste BACHET
Groupe Hospitalier Universitaire Ambroise Paré (Paris) / Pr Jean-François EMILE
Hôpital de la TIMONE / Dr Sébastien SALAS
Institut Bergonié (Bordeaux) / Pr Jean Michel COINDRE, Dr Isabelle HOSTIEN, Dr Frederic CHIBON
ImmunID Technologies (Grenoble) / N. PASQUAL
Université d’Auvergne/CHU (Clermont Ferrand) / Marc BERGER
INSERM U1035 (Bordeaux) / Jean-Max PASQUET
CNRS 8619-IBBMC (Orsay) / Michel LEPOIVRE
USR3010 – LJC CNRS (Lyon) Equipe Mechano-genetics of the cell / Françoise ARGOUL
Faculté de medicine, U895 (Nice) Cell death differentiation and cancer / Dr Patrick AUBERGER
Principales collaborations internationales
Société ROCHE (Penzberg, Allemagne) Carola RIES
Société GlaxoSmithKline (Brentford, UK/Agnes Goetschel)
Brad NELSON (Victoria British Columbia, Canada)
PHARMAMAR (Carlos GALMARINI, colmenar viejo, espagne)
Publications
-
Hepatitis B virus exploits C-type lectin receptors to hijack cDC1s, cDC2s and pDCs
Ouaguia L, Dufeu-Duchesne T, Leroy V, Decaens T, Reiser JB, Sosa Cuevas E, Durantel D, Valladeau-Guilemond J, Bendriss-Vermare N, Chaperot L, Aspord C. Clinical & Translational Immunology
BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patientsSosa Cuevas E, Ouaguia L, Mouret S, Charles J, De Fraipont F, Manches O, Valladeau-Guilemond J, Bendriss-Vermare N, Chaperot L, Aspord C. Clinical & Translational Immunology
Neoadjuvant immune checkpoint inhibitors in cancer, current state of the artO Le Saux, Y Lounici, P Wajda, S Barrin, C Caux, B Dubois, and I Ray-Coquard. Critical Reviews in Oncology/hematology
Expression of TAM-R in human immune cells and unique regulatory function of MERTK in IL-10 production by tolerogenic DC. Giroud, S. Renaudineau, L. Gudefin, A. Calcei, T. Menguy, C. Rozan, J. Mizrahi, C. Caux, V. Duong and J. Valladeau-Guilemond Frontiers Immunology
Inflammasome Deletion Promotes Anti-tumor NK Cell Function in an IL-1/IL-18 Independent Way in Murine Invasive Breast CancerGuey B, Bodnar-Wachtel M, Drouillard A, Eberhardt A, Pratviel M, Goutagny N, Bendriss-Vermare N, Puisieux I, Caux C, Walzer T, Petrilli V. Frontiers in Oncology
Compared descriptive analysis of immunologic landscape in soft tissue sarcoma and GISTDufresne A, Lesluyes T, Ménétrier-Caux C, Brahmi M, Darbo E, Toulmonde M, Italiano A, Mir O, Le Cesne A, Le Guellec S, Valentin T, Chevreau C, Bonvalot S, Penel N, Coindre JM, Caux C, Blay JY, Chibon F. OncoImmunology
Durable and controlled depletion of neutrophils in miceBoivin G, Faget J, Ancey PB, Gkasti A, Mussard J, Engblom C, Pfirschke C, Contat C, Pascual J, Vazquez J, Bendriss-Vermare N, Caux C, Vozenin MC, Pittet MJ, Gunzer M, Meylan E. Nature Communications
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancerHubert M, Gobbini E, Couillault C, Manh TV, Doffin AC, Berthet J, Rodriguez C, Ollion V, Kielbassa J, Sajous C, Treilleux I, Tredan O, Dubois B, Dalod M, Bendriss-Vermare N, Caux C*, Valladeau-Guilemond J*. (*co-last authorship) Science Immunology
CD163+ TAMs accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytesRamos RN, Rodriguez C, Hubert M, Ardin M, Treilleux I, Ries CH, Lavergne E, Chabaud S, Colombe A, Trédan O, Gomes Guedes H, Laginha F, Richer W, Piaggio E, Barbuto JAM, Caux C*, Ménétrier-Caux C*, and Bendriss-Vermare N*(* co-last authorship) Clinical & Translational Immunology
Le rôle des lymphocytes T régulateurs dans l’activité anti-tumorale des anti-CTLA-4Thierry K & Ménétrier-Caux C. Médecine & Science
-
Hepatitis B Virus-induced modulation of liver macrophage function promotes hepatocyte infection
Faure-Dupuy S, Delphin M, Aillot L, Dimier L, Lebossé F., Fresquet J, Parent R, Matter MS, Rivoire M, Bendriss-Vermare N, Salvetti A, Heide D, Flores L, Klumpp K, Lam A, Zoulim F, Heikenwaelder M, Durantel D, and Lucifora J Journal of Hepatology
Methotrexate restores CD73 expression on Th1.17 in rheumatoid arthritis and psoriatic arthritis patients and may contribute to its anti-inflammatory effect through Ado productionBossennec M, Rodriguez C, Hubert M, Di-Roio A, Machon C, Jérôme Guitton J, Battiston-Montagne P, Couturier M, Marotte H, Caux C, Coury F, Ménétrier-Caux C. Journal of Clinical Medicine
Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockadeShekarian T, Sivado E, Jallas AC, Depil S, Kielbassa J, Janoueix-Lerosey I, Hutter G, Goutagny N, Bergeron C, Viari A, Valsesia-Wittmann S, Caux C, Marabelle A. Sci Transl Med.
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cellsMastelic-Gavillet B, xNavarro Rodrigo B, Décombaz L, Wang H, Ercolano G, Rita Ahmed1, Elena Lozano L, Ianaro A, Derré L, Valerio M, Tawadros T, Jichlinski P, Tu Nguyen-Ngoc T, Speiser DE, Verdeil G, Gestermann N, Dormond O, Kandalaft L, Coukos G, Jandus C, Ménétrier-Caux C, Caux C, Ho PC, Romero P, Harari A, Vigano S Journal of Immunotherapy of Cancer
Neutrophil heterogeneity in cancer: from biology to therapiesLecot P, Sarabi M, Pereira Abrantes M, Mussard J, Koenderman L, Caux C, Bendriss-Vermare N, Michallet M-C. Frontiers in Immunology.
Human tumor-infiltrating dendritic cells: from in situ visualization to high throughput analysesHubert M, Gobbini E, Bendriss-Vermare N, Caux C, Valladeau-Guilemond J. Cancers
Targeting adenosine in cancer immunotherapy to enhance T-cell functionVigano S, Alatzoglou D, Irving M, Ménétrier Caux C, Caux C, Romero P, Coukos G Frontiers in Immunology
A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune systemBurlion A, Ramos RN, Pukar KC, Sendeyo K, Corneau A, Ménétrier-Caux C, Piaggio E, Olive D, Caux C and Marodon G Oncoimmunology
Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?Ménétrier-Caux C, Ray-Coquard I, Blay JY, Caux C Journal for Immunotherapy of Cancer
Cold tumors: a therapeutic challenge for immunotherapyBonaventura P, Shekarian T, Alcazer V, Valladeau-Guilermond J, Valsesia-Wittmann S, Amigorena S. et al Frontiers in Immunology
Circulating and hepatic BDCA1+, BDCA2+, and BDCA3+ dendritic cells are subverted in patients with chronic HBV infectionOuaguia L, Leroy V, Dufeu-Duchesne T, Durantel D, Decaens T, Hubert M, Valladeau-Guilemond J, Bendriss-Vermare N, Chaperot L, Aspord C Frontiers in Immunology
Neoepitopes-based vaccines: challenges and perspectivesAlcazer V, Bonaventura P, Tonon L, Wittmann S, Caux C, Depil S Eur J Cancer
CD73 expression in normal and pathological human hepatobiliopancreatic tissues.Sciarra A, Monteiro I, Ménétrier-Caux C, Caux C, Gilbert B, Halkic N, La Rosa S, Romero P, Sempoux C, de Leval L. Cancer Immunol Immunother
-
Immunotherapy and targeted therapy, a promising combination to fight cancer
Andrieu N, Bendriss-Vermare N Med Sci
Contribution of B lymphocytes in acquired resistance to targeted therapies in metastatic melanomaFourneaux C, Dubois B. Med Sci
Hepatitis B Virus Blocks the CRE/CREB Complex and Prevents TLR9 Transcription and Function in Human B CellsTout I, Gomes M, Ainouze M, Marotel M, Pecoul T, Durantel D, Vaccarella S, Dubois B, Loustaud-Ratti V, Walzer T, Alain S, Chemin I, Hasan U J Immunol .
MAVS deficiency induces gut dysbiotic microbiota conferring a pro-allergic phenotypePlantamura E, Dzutsev A, Chamaillard M, Djebali S, Moudombi L, Boucinha L, Grau M, Macari C, Bauché D, Dumitrescu O, Rasigade JP, Lippens S, Plateroti M, Kress E, Cesaro A, Bondu C, Lina G, Bentaher-Belaaouaj A, Marie J, Caux C, Trinchieri G, Marvel J, Michallet MC Proc Natl Acad Sci U S A
MDR1 in immunity: friend or foe?Bossennec M, Di Roio A, Caux C, Ménétrier Caux C. ONcoimmunology
Développement des CAR-T dans les tumeurs solidesAlcazer V, Delenda C, Poirot L, Depil S Bull Cancer
Nouvelles approches vaccinales en cancérologie.Depil S, Bonaventura P, Alcazer V, Tonon L. Bull Cancer
-
BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells
Combes A, Camosseto V, N’Guessan P, Argüello RJ, Mussard J, Caux C, Bendriss-Vermare N, Pierre P & and Gatti E Nature Communications
Cancer immunotherapy via systemic RNA delivery to dendritic cellsRichaud M and Bendriss-Vermare N. Med
Infiltrated B cells promote pancreatic ductal adenocarcinomaSeillet C and Dubois B Med Sci
Neutrophil: an infiltrated agent with new antitumor skillsMazet J, Michallet MC. Med Sci
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockadeFoy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, Albaret MA, Ortiz-Cuaran S, Thomas E, Colombe A, Py C, Gadot N, Michot JP, Fayette J, Viari A, Van den Eynde B, Goudot P, Devouassoux-Shisheboran M, Puisieux A, Caux C, Zrounba P, Lantuejoul S, Saintigny P. Ann Oncol
Emerging role of the Unfolded Protein Response in Tumor Immunosurveillance.Vanacker H, Vetters J, Moudombi L, Caux C, Janssens S, Michallet MC. Trends Cancer .
Cross Talk between Inhibitory Immunoreceptor Tyrosine-Based Activation Motif-Signaling and Toll-Like Receptor Pathways in Macrophages and Dendritic CellsHirsch I, Janovec V, Stranska R, Bendriss-Vermare N Front Immunol .